Arcellx Inc (ACLX) Partners With Gilead

Gilead Sciences is devoting another $200 million to its existing partnership with Arcellx the biotechnology companies said Wednesday. Kite, a Gilead (ticker: GILD) company, has exercised an option to negotiate a license for Arcellx ‘s ARC-SparX program, ACLX-001, in multiple myeloma. The companies said they also expanded the scope of their collaboration for Arcellx’s CART-ddBCMA to include lymphomas.
Arcellx Inc (ACLX) stock has risen 164.62% over the last 12 months.

Arcellx Inc (ACLX) stock is higher by 6.82% while the S&P 500 has risen 0.03% as of 12:43 PM on Thursday, Nov 16. ACLX has risen $3.41 from the previous closing price of $49.99 on volume of 440,137 shares. Over the past year the S&P 500 has risen 13.78% while ACLX has risen 164.62%. ACLX lost -$2.78 per share in the over the last 12 months.

Arcellx Inc (ACLX) Company Description
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.

Price Momentum
ACLX is trading near the top of its 52-week range and above its 200-day simple moving average.

What does this mean?
Investors have been pushing the share price higher, and the stock still appears to have upward momentum. This is a positive sign for the stock's future value.